Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2036042 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $46.78Day +4.40%Mkt cap $2.1B1Y +163.5%Off 52W high −8.8%Vol (1Y) 79.1%
Daily closing price, split-adjusted to the current basis; 1.4y shown of 360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.6% of sh out |
| Days to cover11.5d |
| 13F net flow (QoQ)+0.64% |
| Top-10 13F concentration74.4% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$85.6M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+13.7% |
| 1Y+163.5% |
| Since incept. (ann.)+53.0% |
Total return through 2026-07-30 · series begins 2025-02-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)79.1% |
| Ann. volatility (3Y)87.3% |
| Sharpe (1Y)1.62 |
| Sharpe (3Y)0.93 |
| Max drawdown (1Y)−26.7% |
| Max drawdown (3Y)−69.4% |
| Beta (3Y vs SPY)1.21 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9M | $397M | 22.01% | +0.0% |
| TPG GP A, LLC | 6.5M | $260M | 14.43% | −3.7% |
| ORBIMED ADVISORS LLC | 3.5M | $142M | 7.85% | −0.9% |
| VIKING GLOBAL INVESTORS LP | 3.2M | $128M | 7.10% | +0.0% |
| Atlas Venture Life Science Advisors, LLC | 3.0M | $120M | 6.66% | +0.0% |
| ENAVATE SCIENCES GP, LLC | 2.5M | $99M | 5.51% | +0.0% |
| JENNISON ASSOCIATES LLC | 1.5M | $58M | 3.23% | +30.1% |
| JPMORGAN CHASE & CO | 1.5M | $54M | 3.26% | +18.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 101.4% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 4,230,439 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.60 | — | — | — |
| 2025-09-30 | 2025-11-05 | −$0.46 | — | — | — |
| 2025-06-30 | 2025-08-11 | −$410.00 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.62 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 86d) — not company-confirmed.
